MED23

Summary

MED23 (mediator complex subunit 23, HGNC:2372) is a protein-coding gene on chromosome 6q23.2, encoding Mediator of RNA polymerase II transcription subunit 23 (Q9ULK4). Required for transcriptional activation subsequent to the assembly of the pre-initiation complex. It is a selective cancer dependency (DepMap: 20.4% of cell lines).

The activation of gene transcription is a multistep process that is triggered by factors that recognize transcriptional enhancer sites in DNA. These factors work with co-activators to direct transcriptional initiation by the RNA polymerase II apparatus. The protein encoded by this gene is a subunit of the CRSP (cofactor required for SP1 activation) complex, which, along with TFIID, is required for efficient activation by SP1. This protein is also a component of other multisubunit complexes e.g. thyroid hormone receptor-(TR-) associated proteins which interact with TR and facilitate TR function on DNA templates in conjunction with initiation factors and cofactors. This protein also acts as a metastasis suppressor. Several alternatively spliced transcript variants encoding different isoforms have been described for this gene.

Source: NCBI Gene 9439 — RefSeq curated summary.

At a glance

• Gene–disease (curated): intellectual disability, autosomal recessive 18 (Strong, GenCC) — +2 more curated relationships
• GWAS associations: 2
• Clinical variants (ClinVar): 347 total — 16 pathogenic, 15 likely-pathogenic
• Phenotypes (HPO): 26
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 1 cancer types
• Cancer dependency (DepMap): dependent in 20.4% of screened cell lines
• MANE Select transcript: NM_004830

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2372
Approved symbol	MED23
Name	mediator complex subunit 23
Location	6q23.2
Locus type	gene with protein product
Status	Approved
Aliases	CRSP130, DRIP130, Sur2
Ensembl gene	ENSG00000112282
Ensembl biotype	protein_coding
OMIM	605042
Entrez	9439

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 7 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000354577, ENST00000368053, ENST00000368058, ENST00000368060, ENST00000368068, ENST00000479213, ENST00000484885, ENST00000489888, ENST00000539158, ENST00000883258

RefSeq mRNA: 12 — MANE Select: NM_004830 NM_001270521, NM_001270522, NM_001376517, NM_001376518, NM_001376519, NM_001376520, NM_001376521, NM_001376522, NM_001376523, NM_001376524, NM_004830, NM_015979

CCDS: CCDS5146, CCDS5147, CCDS59039

Canonical transcript exons

ENST00000368068 — 29 exons

Exon	Start	End
ENSE00000763903	131598556	131598761
ENSE00000763904	131598287	131598467
ENSE00000763906	131596518	131596688
ENSE00000763923	131593006	131593171
ENSE00001239178	131595947	131596163
ENSE00001239211	131592388	131592460
ENSE00001360585	131586732	131587846
ENSE00002433787	131623351	131623462
ENSE00002435309	131615907	131616002
ENSE00002440561	131624865	131624989
ENSE00002443375	131604178	131604320
ENSE00002445073	131619827	131619896
ENSE00002450530	131621881	131621979
ENSE00002454886	131602218	131602381
ENSE00002462934	131618407	131618519
ENSE00002484276	131605240	131605485
ENSE00002486990	131600038	131600162
ENSE00002496051	131606479	131606624
ENSE00002519291	131627396	131627483
ENSE00002521411	131620628	131620729
ENSE00002524881	131607928	131608071
ENSE00002536568	131610046	131610246
ENSE00003553030	131589465	131589596
ENSE00003584394	131627641	131627672
ENSE00003588291	131591313	131591527
ENSE00003601507	131594099	131594335
ENSE00003605356	131590322	131590442
ENSE00003655610	131603030	131603204
ENSE00003843964	131628011	131628242

Expression profiles

Bgee: expression breadth ubiquitous, 283 present calls, max score 91.73.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.9427 / max 188.4298, expressed in 1809 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
75558	14.6655	1799
75557	2.2772	1171

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	91.73	gold quality
calcaneal tendon	UBERON:0003701	91.48	gold quality
cerebellar hemisphere	UBERON:0002245	91.44	gold quality
cerebellar cortex	UBERON:0002129	91.38	gold quality
adrenal tissue	UBERON:0018303	91.33	gold quality
choroid plexus epithelium	UBERON:0003911	90.81	gold quality
cerebellum	UBERON:0002037	90.67	gold quality
endometrium	UBERON:0001295	90.46	gold quality
body of pancreas	UBERON:0001150	90.09	gold quality
mucosa of paranasal sinus	UBERON:0005030	89.98	gold quality
mucosa of sigmoid colon	UBERON:0004993	89.91	gold quality
secondary oocyte	CL:0000655	89.60	gold quality
pylorus	UBERON:0001166	89.48	gold quality
colonic epithelium	UBERON:0000397	89.31	gold quality
bone marrow cell	CL:0002092	89.22	gold quality
rectum	UBERON:0001052	89.14	gold quality
germinal epithelium of ovary	UBERON:0001304	89.10	gold quality
jejunal mucosa	UBERON:0000399	89.09	gold quality
urethra	UBERON:0000057	89.04	gold quality
right uterine tube	UBERON:0001302	89.00	gold quality
colonic mucosa	UBERON:0000317	88.93	gold quality
palpebral conjunctiva	UBERON:0001812	88.71	gold quality
ovary	UBERON:0000992	88.67	gold quality
left ovary	UBERON:0002119	88.64	gold quality
body of uterus	UBERON:0009853	88.59	gold quality
thyroid gland	UBERON:0002046	88.56	gold quality
right lobe of thyroid gland	UBERON:0001119	88.54	gold quality
left lobe of thyroid gland	UBERON:0001120	88.53	gold quality
mucosa of stomach	UBERON:0001199	88.51	gold quality
uterus	UBERON:0000995	88.44	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.52

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
KISS1	Activation
TXNIP	Unknown

Upstream regulators (CollecTRI, top): ELF3, STAT1

miRNA regulators (miRDB)

34 targeting MED23, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-1290	99.59	69.90	2079
HSA-MIR-516A-3P	99.46	67.96	1378
HSA-MIR-516B-3P	99.46	67.96	1378
HSA-MIR-7162-5P	99.46	68.08	1368
HSA-MIR-1276	99.36	68.18	1642
HSA-MIR-520F-5P	99.34	70.40	1632
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-361-3P	99.19	66.45	1381
HSA-MIR-628-3P	99.04	68.37	814
HSA-MIR-6737-3P	98.95	68.56	1577
HSA-MIR-7157-3P	98.95	68.70	1582
HSA-MIR-219A-1-3P	98.91	67.87	639
HSA-MIR-6889-3P	98.84	67.35	1198
HSA-MIR-5008-3P	98.73	67.50	1433
HSA-MIR-606	98.72	67.34	960
HSA-MIR-583	98.71	67.44	1791
HSA-MIR-6529-3P	98.68	66.76	1020
HSA-MIR-1246	98.54	66.21	959
HSA-MIR-3187-5P	98.36	65.74	1776
HSA-MIR-541-5P	98.24	67.77	1181
HSA-MIR-6881-3P	98.04	68.24	1777
HSA-MIR-3664-3P	97.85	67.62	1452
HSA-MIR-1285-3P	97.72	67.02	1932
HSA-MIR-5189-5P	97.72	66.96	1814
HSA-MIR-618	97.62	67.46	861
HSA-MIR-612	97.26	65.95	1597
HSA-MIR-6860	97.21	66.31	1656

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 20.4% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 17)

• Sur2(CRSP3) is required for activation by Adenovirus E1A CR3 activation domain and is required for MAPK-mediated activation of Elk-1. (PMID:11934987)
• DRIP130 regulates HER2 expression by binding to ESX (PMID:12242338)
• loss of DRIP-130 expression, as a result of the gross loss of human chromosome 6q16.3-q23, provokes increased tumor metastasis (PMID:16964286)
• missense mutation (p. R617Q) in MED23 that cosegregates with nonsyndromic autosomal recessive intellectual disability; mutation impaired response of JUN and FOS to mitogens by altering interaction between enhancer-bound transcription factors and Mediator (PMID:21868677)
• Data show that Med23 RNAi specifically inhibits the proliferation and tumorigenicity of lung cancer cells with hyperactive Ras activity. (PMID:22988093)
• Mediator MED23 regulates basal transcription in vivo via an interaction with P-TEFb. (PMID:23340209)
• Upregulation of mediator MED23 in non-small-cell lung cancer promotes the growth, migration, and metastasis of cancer cells. (PMID:25273169)
• MED23 plays an important role in hepatocarcinogenesis, and it may be a novel target for HCC therapy. (PMID:25684393)
• MED23-associated intellectual disability has been found in two brothers from a non-consanguineous family. (PMID:25845469)
• intra-tumor heterogeneity data suggest that there could be an under- or over-estimation of the occurrence of MED23 frameshift mutations in microsatellite instability-high colorectal cancers (PMID:26152846)
• This is the first patient with documented refractory epilepsy caused by a novel homozygous pathogenic variant in MED23 expanding the phenotypic spectrum. Identification of the underlying genetic defect in MED23 sheds light on the possible mechanism of complete response to the ketogenic diet in this child. (PMID:27311965)
• a 7-gene signature was identified which correctly predicted the primary prefibrotic myelofibrosis group with a sensitivity of 100% and a specificity of 89%. The 7 genes included MPO, CEACAM8, CRISP3, MS4A3, CEACAM6, HEMGN, and MMP8 (PMID:27579896)
• Higher l-arginine was associated with higher risk of Ischemic heart disease (odds ratio and of myocardial infarction, based on 2 SNPs from MED23. (PMID:27914500)
• MED23 adopts an arch-shaped conformation, with an N-terminal domain (Nter) protruding from a large core region. (PMID:30140054)
• LINC00921 reduces lung cancer radiosensitivity by destabilizing NUDT21 and driving aberrant MED23 alternative polyadenylation. (PMID:37999979)
• MED23 pathogenic variant: genomic-phenotypic analysis. (PMID:39144687)
• MED23 depletion induces premature senescence in NSCLC cells by interacting with BCLAF1 and then suppressing NUPR1 expression. (PMID:39366174)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	med23	ENSDARG00000029157
mus_musculus	Med23	ENSMUSG00000019984
rattus_norvegicus	Med23	ENSRNOG00000013422
drosophila_melanogaster	MED23	FBGN0034795
caenorhabditis_elegans	sur-2	WBGENE00006349

Protein

Protein identifiers

Mediator of RNA polymerase II transcription subunit 23 — Q9ULK4 (reviewed: Q9ULK4)

Alternative names: Activator-recruited cofactor 130 kDa component, Cofactor required for Sp1 transcriptional activation subunit 3, Mediator complex subunit 23, Protein sur-2 homolog, Transcriptional coactivator CRSP130, Vitamin D3 receptor-interacting protein complex 130 kDa component

All UniProt accessions (2): Q9ULK4, Q5JWT2

UniProt curated annotations — full annotation on UniProt →

Function. Required for transcriptional activation subsequent to the assembly of the pre-initiation complex. Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional pre-initiation complex with RNA polymerase II and the general transcription factors. Required for transcriptional activation by adenovirus E1A protein. Required for ELK1-dependent transcriptional activation in response to activated Ras signaling.

Subunit / interactions. Interacts with ELK1. Component of the Mediator complex, which is composed of MED1, MED4, MED6, MED7, MED8, MED9, MED10, MED11, MED12, MED13, MED13L, MED14, MED15, MED16, MED17, MED18, MED19, MED20, MED21, MED22, MED23, MED24, MED25, MED26, MED27, MED29, MED30, MED31, CCNC, CDK8 and CDC2L6/CDK11. The MED12, MED13, CCNC and CDK8 subunits form a distinct module termed the CDK8 module. Mediator containing the CDK8 module is less active than Mediator lacking this module in supporting transcriptional activation. Individual preparations of the Mediator complex lacking one or more distinct subunits have been variously termed ARC, CRSP, DRIP, PC2, SMCC and TRAP. Interacts with CEBPB (when not methylated), CTNNB1, and GLI3. Interacts with the adenovirus E1A protein.

Subcellular location. Nucleus.

Disease relevance. Intellectual developmental disorder, autosomal recessive 18, with or without epilepsy (MRT18) [MIM:614249] A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the Mediator complex subunit 23 family.

Isoforms (6)

UniProt ID	Names	Canonical?
Q9ULK4-1	1	yes
Q9ULK4-2	2
Q9ULK4-3	3
Q9ULK4-4	4
Q9ULK4-5	5
Q9ULK4-6	6

RefSeq proteins (12): NP_001257450, NP_001257451, NP_001363446, NP_001363447, NP_001363448, NP_001363449, NP_001363450, NP_001363451, NP_001363452, NP_001363453, NP_004821, NP_057063 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR021629	Mediator_Med23	Family

Pfam: PF11573

UniProt features (137 total): helix 87, strand 18, turn 13, sequence conflict 8, splice variant 7, chain 1, region of interest 1, sequence variant 1, compositionally biased region 1

Structure

Experimental structures (PDB)

13 structures.

PDB	Method	Resolution (Å)
6H02	X-RAY DIFFRACTION	2.8
9F6Y	ELECTRON MICROSCOPY	2.98
9F76	ELECTRON MICROSCOPY	3.1
7EMF	ELECTRON MICROSCOPY	3.5
8TRH	ELECTRON MICROSCOPY	3.7
7ENA	ELECTRON MICROSCOPY	4.07
7ENC	ELECTRON MICROSCOPY	4.13
8GXS	ELECTRON MICROSCOPY	4.16
7ENJ	ELECTRON MICROSCOPY	4.4
8T9D	ELECTRON MICROSCOPY	4.66
7LBM	ELECTRON MICROSCOPY	4.8
8GXQ	ELECTRON MICROSCOPY	5.04
8TQW	ELECTRON MICROSCOPY	8.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9ULK4-F1	87.30	0.57

Antibody-complex structures (SAbDab): 1 — 6H02

Function

Pathways and Gene Ontology

Reactome pathways

20 pathways

ID	Pathway
R-HSA-1989781	PPARA activates gene expression
R-HSA-212436	Generic Transcription Pathway
R-HSA-381340	Transcriptional regulation of white adipocyte differentiation
R-HSA-9833110	RSV-host interactions
R-HSA-9841922	MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
R-HSA-1266738	Developmental Biology
R-HSA-1430728	Metabolism
R-HSA-1643685	Disease
R-HSA-212165	Epigenetic regulation of gene expression
R-HSA-400206	Regulation of lipid metabolism by PPARalpha
R-HSA-556833	Metabolism of lipids
R-HSA-5663205	Infectious disease
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-9818564	Epigenetic regulation of gene expression by MLL3 and MLL4 complexes
R-HSA-9820952	Respiratory Syncytial Virus Infection Pathway
R-HSA-9824446	Viral Infection Pathways
R-HSA-9843745	Adipogenesis
R-HSA-9851695	Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes
R-HSA-9917777	Epigenetic regulation by WDR5-containing histone modifying complexes

MSigDB gene sets: 271 (showing top): REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, GOBP_POSITIVE_REGULATION_OF_LYMPHOCYTE_MIGRATION, GOBP_POSITIVE_REGULATION_OF_CELLULAR_EXTRAVASATION, GOBP_REGULATION_OF_LEUKOCYTE_MIGRATION, GOBP_REGULATION_OF_MONONUCLEAR_CELL_MIGRATION, GOBP_CELLULAR_EXTRAVASATION, GOBP_LEUKOCYTE_MIGRATION, GOBP_POSITIVE_REGULATION_OF_LEUKOCYTE_MIGRATION, GOBP_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, GOBP_REGULATION_OF_CELLULAR_EXTRAVASATION, GOBP_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, GOBP_TRANSCRIPTION_INITIATION_AT_RNA_POLYMERASE_II_PROMOTER, GOBP_T_CELL_MIGRATION, GOBP_PROTEIN_DNA_COMPLEX_ORGANIZATION

GO Biological Process (8): regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), transcription initiation at RNA polymerase II promoter (GO:0006367), positive regulation of gene expression (GO:0010628), positive regulation of transcription elongation by RNA polymerase II (GO:0032968), RNA polymerase II preinitiation complex assembly (GO:0051123), positive regulation of transcription initiation by RNA polymerase II (GO:0060261), positive regulation of T cell extravasation (GO:2000409)

GO Molecular Function (2): transcription coactivator activity (GO:0003713), protein binding (GO:0005515)

GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), transcription regulator complex (GO:0005667), mediator complex (GO:0016592), core mediator complex (GO:0070847)

Reactome top-level categories

Rollup of top-15 pathways:

Category	Pathways
Gene expression (Transcription)	2
Regulation of lipid metabolism by PPARalpha	1
RNA Polymerase II Transcription	1
Adipogenesis	1
Respiratory Syncytial Virus Infection Pathway	1
Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes	1
Metabolism of lipids	1
Metabolism	1
Disease	1
Epigenetic regulation by WDR5-containing histone modifying complexes	1
Viral Infection Pathways	1
Infectious disease	1
Developmental Biology	1
Epigenetic regulation of gene expression by MLL3 and MLL4 complexes	1
Epigenetic regulation of gene expression	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of gene expression	2
transcription by RNA polymerase II	2
positive regulation of transcription by RNA polymerase II	2
transcription initiation at RNA polymerase II promoter	2
DNA-templated transcription	1
regulation of RNA biosynthetic process	1
regulation of DNA-templated transcription	1
DNA-templated transcription initiation	1
gene expression	1
positive regulation of macromolecule biosynthetic process	1
transcription elongation by RNA polymerase II	1
positive regulation of DNA-templated transcription, elongation	1
regulation of transcription elongation by RNA polymerase II	1
transcription preinitiation complex assembly	1
regulation of transcription initiation by RNA polymerase II	1
positive regulation of DNA-templated transcription initiation	1
positive regulation of cellular extravasation	1
T cell extravasation	1
positive regulation of T cell migration	1
regulation of T cell extravasation	1
transcription coregulator activity	1
positive regulation of DNA-templated transcription	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
protein-containing complex	1
core mediator complex	1
nuclear protein-containing complex	1
RNA polymerase II transcription regulator complex	1

Protein interactions and networks

STRING

1594 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MED23	MED15	Q96RN5	969
MED23	MED14	O60244	964
MED23	MED16	Q9Y2X0	961
MED23	MED12	Q93074	945
MED23	MED4	Q9NPJ6	941
MED23	MED13	Q9UHV7	888
MED23	ELK1	P19419	870
MED23	MED22	Q15528	851
MED23	MED1	Q15648	850
MED23	MED6	O75586	832
MED23	IRF7	Q92985	822
MED23	MED17	Q9NVC6	817
MED23	MED26	O95402	808
MED23	CDK8	P49336	805
MED23	MED21	Q13503	787

IntAct

140 interactions, top by confidence:

A	B	Type	Score
MED10	MED19	psi-mi:“MI:0914”(association)	0.910
MED10	MED19	psi-mi:“MI:0915”(physical association)	0.910
CDK8	MED14	psi-mi:“MI:0914”(association)	0.900
MED4	MED19	psi-mi:“MI:0914”(association)	0.900
MED29	MED19	psi-mi:“MI:0914”(association)	0.890
MED21	MED19	psi-mi:“MI:0914”(association)	0.880
CDK8	MED19	psi-mi:“MI:2364”(proximity)	0.850
CDK8	MED19	psi-mi:“MI:0914”(association)	0.850
MED20	MED19	psi-mi:“MI:0914”(association)	0.840
MED31	MED19	psi-mi:“MI:0914”(association)	0.840
MED7	MED19	psi-mi:“MI:0914”(association)	0.840
MED11	MED19	psi-mi:“MI:0914”(association)	0.840
MED18	MED19	psi-mi:“MI:0914”(association)	0.840

BioGRID (421): MED23 (Reconstituted Complex), MED23 (Phenotypic Suppression), MED23 (Affinity Capture-MS), MED23 (Affinity Capture-MS), MED23 (Affinity Capture-MS), MED23 (Affinity Capture-MS), MED23 (Affinity Capture-MS), MED23 (Affinity Capture-MS), MED23 (Affinity Capture-MS), MED23 (Affinity Capture-MS), MED23 (Affinity Capture-MS), MED23 (Affinity Capture-Western), MED10 (Co-fractionation), MED14 (Co-fractionation), MED22 (Co-fractionation)

ESM2 similar proteins: A1Z8X3, A1ZAK1, G5ED39, H2QII6, O01510, O08662, O94668, P42173, P42286, P49792, Q00416, Q03280, Q0IEK6, Q10573, Q10669, Q13535, Q18508, Q18892, Q196Z9, Q29L39, Q2U639, Q5EAK6, Q5EB59, Q5RIW8, Q5ZKU4, Q61CW2, Q61WP7, Q6CP76, Q6CT34, Q6V3W0, Q70PP2, Q751J3, Q756G2, Q75DV4, Q80YQ2, Q8IRS9, Q8IRT0, Q9DE14, Q9GNN7, Q9H0H0

Diamond homologs: Q16HH9, Q5EB59, Q5RIW8, Q6P423, Q80YQ2, Q9ULK4, Q9W1X7

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
MED23	“form complex”	“Core mediator complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 92 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Respiratory Syncytial Virus Infection Pathway	27	74.9×	1e-43
RSV-host interactions	27	59.5×	9e-41
Adipogenesis	27	59.5×	9e-41
Regulation of lipid metabolism by PPARalpha	27	53.6×	2e-39
Transcriptional regulation of white adipocyte differentiation	27	49.4×	2e-38
Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes	15	45.5×	4e-20
Epigenetic regulation of gene expression by MLL3 and MLL4 complexes	15	41.6×	2e-19
PPARA activates gene expression	27	35.9×	3e-34

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of transcription initiation by RNA polymerase II	25	79.9×	8e-40
positive regulation of transcription elongation by RNA polymerase II	22	77.9×	7e-35
RNA polymerase II preinitiation complex assembly	24	76.8×	7e-38
somatic stem cell population maintenance	10	29.2×	3e-10
transcription initiation at RNA polymerase II promoter	6	26.4×	1e-05
protein ubiquitination	12	5.8×	1e-04

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 1 cancer types — BRCA.

Clinical variants and AI predictions

ClinVar

347 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	16
Likely pathogenic	15
Uncertain significance	187
Likely benign	71
Benign	5

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1032717	NM_004830.4(MED23):c.2832dup (p.Val945fs)	Pathogenic
1075875	NM_000045.4(ARG1):c.819del (p.Asp274fs)	Pathogenic
1076486	NM_000045.4(ARG1):c.93del (p.Arg32fs)	Pathogenic
1327487	NM_004830.4(MED23):c.506A>G (p.Tyr169Cys)	Pathogenic
1327489	NM_004830.4(MED23):c.382G>A (p.Gly128Arg)	Pathogenic
1327491	NM_004830.4(MED23):c.1919A>G (p.Gln640Arg)	Pathogenic
143192	NM_004830.4(MED23):c.3638A>G (p.His1213Arg)	Pathogenic
2276892	NM_004830.4(MED23):c.815dup (p.Tyr272Ter)	Pathogenic
2980910	NM_000045.4(ARG1):c.493dup (p.Val165fs)	Pathogenic
423225	NM_004830.4(MED23):c.597+1G>T	Pathogenic
437437	NM_004830.4(MED23):c.670C>G (p.Arg224Gly)	Pathogenic
4813535	NM_004830.4(MED23):c.3983G>C (p.Arg1328Pro)	Pathogenic
557931	NM_000045.4(ARG1):c.129del (p.Glu44fs)	Pathogenic
657467	NM_000045.4(ARG1):c.425del (p.Gly142fs)	Pathogenic
852613	NM_000045.4(ARG1):c.464dup (p.Ile156fs)	Pathogenic
871322	NM_000045.4(ARG1):c.666-2A>G	Pathogenic
1012785	NM_004830.4(MED23):c.1387A>T (p.Arg463Ter)	Likely pathogenic
1029420	NM_004830.4(MED23):c.1181C>T (p.Pro394Leu)	Likely pathogenic
1215415	NM_004830.4(MED23):c.2750G>A (p.Trp917Ter)	Likely pathogenic
1327674	NM_004830.4(MED23):c.3508_3511del (p.Val1171fs)	Likely pathogenic
1726533	NM_000045.4(ARG1):c.637G>T (p.Glu213Ter)	Likely pathogenic
1726742	NM_000045.4(ARG1):c.432_448del (p.Val145fs)	Likely pathogenic
191215	NM_004830.4(MED23):c.479T>C (p.Leu160Pro)	Likely pathogenic
235773	NM_004830.4(MED23):c.1932-1G>A	Likely pathogenic
30442	NM_004830.4(MED23):c.1832G>A (p.Arg611Gln)	Likely pathogenic
3382460	NM_004830.4(MED23):c.3145del (p.Tyr1048_Leu1049insTer)	Likely pathogenic
432703	NM_004830.4(MED23):c.599T>G (p.Leu200Ter)	Likely pathogenic
4685525	NM_000045.4(ARG1):c.545T>G (p.Val182Gly)	Likely pathogenic
559910	NM_004830.4(MED23):c.2368_2371del (p.Leu790fs)	Likely pathogenic
978881	NM_004830.4(MED23):c.953del (p.Glu318fs)	Likely pathogenic

SpliceAI

6028 predictions. Top by Δscore:

Variant	Effect	Δscore
6:131579252:G:GT	donor_gain	1.0000
6:131581217:A:G	acceptor_gain	1.0000
6:131581218:G:GG	acceptor_gain	1.0000
6:131581375:A:T	donor_gain	1.0000
6:131582716:G:GG	donor_gain	1.0000
6:131583353:A:G	acceptor_gain	1.0000
6:131583740:A:AG	acceptor_gain	1.0000
6:131583741:G:GG	acceptor_gain	1.0000
6:131587843:CTAC:C	acceptor_gain	1.0000
6:131589461:TTA:T	donor_loss	1.0000
6:131589462:TA:T	donor_loss	1.0000
6:131589463:A:AC	donor_gain	1.0000
6:131589463:AC:A	donor_loss	1.0000
6:131589464:C:CT	donor_gain	1.0000
6:131589464:CT:C	donor_gain	1.0000
6:131589464:CTT:C	donor_gain	1.0000
6:131589464:CTTG:C	donor_gain	1.0000
6:131589592:CCAAT:C	acceptor_gain	1.0000
6:131589593:CAAT:C	acceptor_gain	1.0000
6:131589593:CAATC:C	acceptor_gain	1.0000
6:131589594:AATCT:A	acceptor_loss	1.0000
6:131589597:C:CC	acceptor_gain	1.0000
6:131592386:A:AC	donor_gain	1.0000
6:131592387:C:CC	donor_gain	1.0000
6:131592461:C:CC	acceptor_gain	1.0000
6:131592468:C:CT	acceptor_gain	1.0000
6:131592469:G:T	acceptor_gain	1.0000
6:131594158:T:A	donor_gain	1.0000
6:131594198:TTAGA:T	donor_gain	1.0000
6:131594199:TAGAC:T	donor_gain	1.0000

AlphaMissense

9063 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:131587793:G:C	F1331L	1.000
6:131587793:G:T	F1331L	1.000
6:131587795:A:G	F1331L	1.000
6:131587800:A:G	L1329P	1.000
6:131589484:C:T	G1307D	1.000
6:131589496:T:C	Y1303C	1.000
6:131589497:A:G	Y1303H	1.000
6:131589498:C:A	K1302N	1.000
6:131589498:C:G	K1302N	1.000
6:131589500:T:C	K1302E	1.000
6:131589517:T:A	D1296V	1.000
6:131590377:A:G	L1251P	1.000
6:131591353:A:G	W1216R	1.000
6:131591353:A:T	W1216R	1.000
6:131592392:A:G	L1156P	1.000
6:131593113:A:C	F1097L	1.000
6:131593113:A:T	F1097L	1.000
6:131593115:A:G	F1097L	1.000
6:131593122:G:C	F1094L	1.000
6:131593122:G:T	F1094L	1.000
6:131593124:A:G	F1094L	1.000
6:131593125:T:A	R1093S	1.000
6:131593125:T:G	R1093S	1.000
6:131593126:C:G	R1093T	1.000
6:131593130:A:G	W1092R	1.000
6:131593130:A:T	W1092R	1.000
6:131594254:A:G	L1026P	1.000
6:131594305:A:G	L1009P	1.000
6:131594317:A:G	L1005P	1.000
6:131595951:A:C	F997L	1.000

dbSNP variants (sampled 300 via entrez): RS1000094228 (6:131593135 CA>C), RS1000157171 (6:131574975 A>G), RS1000166403 (6:131610000 G>A), RS1000195393 (6:131598065 G>A), RS1000231540 (6:131621697 A>G), RS1000331080 (6:131614131 G>T), RS1000421608 (6:131591258 A>G,T), RS1000451954 (6:131584017 G>T), RS1000488475 (6:131607185 G>A,C), RS1000525126 (6:131589401 T>C), RS1000526551 (6:131593280 C>T), RS1000561522 (6:131587416 C>T), RS1000582041 (6:131621360 C>G), RS1000585240 (6:131591043 C>T), RS1000747067 (6:131628291 C>G,T)

Disease associations

OMIM: gene MIM:605042 | disease phenotypes: MIM:207800, MIM:614249, MIM:617667

GenCC curated gene-disease

Disease	Classification	Inheritance
intellectual disability, autosomal recessive 18	Strong	Autosomal recessive
syndromic intellectual disability	Moderate	Autosomal recessive
autosomal recessive non-syndromic intellectual disability	Supportive	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
syndromic intellectual disability	Moderate	AR

Mondo (7): arginase deficiency (MONDO:0008814), intellectual disability, autosomal recessive 18 (MONDO:0013651), neurodevelopmental disorder (MONDO:0700092), Fraser syndrome 3 (MONDO:0054739), intellectual disability (MONDO:0001071), syndromic intellectual disability (MONDO:0000508), autosomal recessive non-syndromic intellectual disability (MONDO:0019502)

Orphanet (3): Argininemia (Orphanet:90), Autosomal recessive non-syndromic intellectual disability (Orphanet:88616), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

26 total (26 of 26 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000252	Microcephaly
HP:0000737	Irritability
HP:0000750	Delayed speech and language development
HP:0001249	Intellectual disability
HP:0001257	Spasticity
HP:0001263	Global developmental delay
HP:0001266	Choreoathetosis
HP:0001288	Gait disturbance
HP:0001332	Dystonia
HP:0001344	Absent speech
HP:0001629	Ventricular septal defect
HP:0001631	Atrial septal defect
HP:0002187	Profound intellectual disability
HP:0002353	EEG abnormality
HP:0002360	Sleep disturbance
HP:0002474	Expressive language delay
HP:0003577	Congenital onset
HP:0003593	Infantile onset
HP:0007030	Nonprogressive encephalopathy
HP:0008936	Axial hypotonia
HP:0011463	Childhood onset
HP:0011968	Feeding difficulties
HP:0012110	Hypoplasia of the pons
HP:0033725	Thin corpus callosum
HP:0100021	Cerebral palsy

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST002623_1	L-arginine levels	4.000000e-19
GCST006867_54	Type 2 diabetes	2.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0006524	L-arginine measurement

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D020162	Hyperargininemia	C10.228.140.163.100.937.500; C16.320.565.100.940.500; C16.320.565.189.937.500; C18.452.132.100.937.437; C18.452.648.100.940.437; C18.452.648.189.937.437
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2111426 (PROTEIN-PROTEIN INTERACTION), CHEMBL4146 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 13,102 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL189963	PALBOCICLIB	4	13,102

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2781659	ARG1, MED23	3	3.00	1	selective beta-2-adrenoreceptor agonists

Binding affinities (BindingDB)

1 measured of 1 human assays (1 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL2170196	KD	1800 nM

ChEMBL bioactivities

10 potent at pChembl≥5 of 10 total, top 10 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.23	Kd	590	nM	CHEMBL1077445
6.21	Kd	620	nM	CHEMBL1077474
6.00	Kd	1000	nM	CHEMBL1077454
5.75	Kd	1800	nM	WRENCHNOLOL
5.52	Kd	2998	nM	PALBOCICLIB
5.33	Kd	4690	nM	CHEMBL5653589
5.33	ED50	4728	nM	CHEMBL5653589
5.31	Kd	4854	nM	CHEMBL3752910
5.31	ED50	4894	nM	CHEMBL3752910
5.23	Kd	5900	nM	CHEMBL1077475

PubChem BioAssay actives

7 with measured affinity, of 19 total; 7 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
5-[[(3S,5R)-3-(2-hydroxyethyl)-3-(2-methylpropyl)-2-[[4-(trifluoromethyl)phenyl]methyl]-1,2-oxazolidin-5-yl]methylcarbamothioylamino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid	469608: Inhibition of ESX-Med23 interaction in human BT474 cells assessed as down regulation of ErbB2 expression by Western blotting	kd	0.5900	uM
5-[[(3S,5R)-3-(2-hydroxyethyl)-3-(2-methylpropyl)-2-[(4-phenylphenyl)methyl]-1,2-oxazolidin-5-yl]methylcarbamothioylamino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid	469608: Inhibition of ESX-Med23 interaction in human BT474 cells assessed as down regulation of ErbB2 expression by Western blotting	kd	0.6200	uM
5-[[(3S,5R)-3-(2-hydroxyethyl)-3-(2-methylpropyl)-2-(naphthalen-2-ylmethyl)-1,2-oxazolidin-5-yl]methylcarbamothioylamino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid	469608: Inhibition of ESX-Med23 interaction in human BT474 cells assessed as down regulation of ErbB2 expression by Western blotting	kd	1.0000	uM
4-[1-(adamantane-1-carbonyl)piperidin-4-yl]-N-(5-aminopentyl)-N-[2-hydroxy-3-[1-(4-methylphenyl)sulfonylindol-4-yl]oxypropyl]piperidine-1-carboxamide	700859: Binding affinity to Sur2	kd	1.8000	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148741: Binding affinity to human MED23 incubated for 45 mins by Kinobead based pull down assay	kd	4.6896	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148741: Binding affinity to human MED23 incubated for 45 mins by Kinobead based pull down assay	kd	4.8541	uM
5-[[(3S,5R)-2-benzyl-3-(2-hydroxyethyl)-3-(2-methylpropyl)-1,2-oxazolidin-5-yl]methylcarbamothioylamino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid	469608: Inhibition of ESX-Med23 interaction in human BT474 cells assessed as down regulation of ErbB2 expression by Western blotting	kd	5.9000	uM

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Formaldehyde	decreases expression, increases expression	2
Valproic Acid	affects expression, decreases expression	2
aristolochic acid I	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases expression, increases abundance	1
arsenite	affects binding, decreases reaction	1
methacrylaldehyde	affects cotreatment, increases expression, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Zoledronic Acid	affects cotreatment, increases expression	1
Fluvastatin	affects cotreatment, increases expression	1
Acrolein	affects cotreatment, increases expression, increases abundance	1
Air Pollutants	affects cotreatment, increases abundance, increases expression	1
Cisplatin	increases expression	1
Diethylhexyl Phthalate	decreases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects expression	1
Ethyl Methanesulfonate	increases expression	1
Ivermectin	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Ozone	affects cotreatment, increases expression, increases abundance	1
Plant Extracts	increases expression, affects cotreatment	1
Testosterone	decreases expression	1
Thiram	increases expression	1
Urethane	increases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	1
Aflatoxin B1	decreases methylation	1

ChEMBL screening assays

9 unique, capped per target: 9 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1099983	Binding	Inhibition of ESX-Med23 interaction in human BT474 cells assessed as down regulation of ErbB2 expression up to 50 uM by Western blotting	Inhibition of ErbB2(Her2) expression with small molecule transcription factor mimics. — Bioorg Med Chem Lett

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9K4	Ubigene HEK293 MED23 KO	Transformed cell line	Female

Clinical trials (associated diseases)

288 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT03921541	PHASE3	COMPLETED	Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency
NCT05676853	PHASE3	TERMINATED	A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT03378531	PHASE2	COMPLETED	A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT02488044	PHASE1/PHASE2	COMPLETED	A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency
NCT01421888	Not specified	TERMINATED	The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity
NCT03655223	Not specified	ENROLLING_BY_INVITATION	Early Check: Expanded Screening in Newborns
NCT04612764	Not specified	ACTIVE_NOT_RECRUITING	Liver Disease in Urea Cycle Disorders
NCT04908319	Not specified	RECRUITING	Hepatic Histopathology in Urea Cycle Disorders
NCT05412160	Not specified	COMPLETED	Improving Quality of Life and Daily Life Activities With Bioarginine in Patients With COPD
NCT05687474	Not specified	COMPLETED	Baby Detect : Genomic Newborn Screening
NCT05910151	Not specified	UNKNOWN	Selective Screening of Children for Hereditary Metabolic Diseases by Tandem Mass Spectrometry in Kazakhstan
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy